CONDUCTING CLINICAL RESEARCH IN THE NEW NHS - THE MODEL OF CANCER

被引:41
作者
SMYTH, JF
MOSSMAN, J
HALL, R
HEPBURN, S
PINKERTON, R
RICHARDS, M
THATCHER, N
BOX, J
机构
[1] UNITED KINGDOM COORDINATING COMM CANC RES,LONDON WC2A 3PX,ENGLAND
[2] FREEMAN RD HOSP,DEPT UROL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND
[3] ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND
[4] GUYS HOSP,IMPERIAL CANC RES FUND,BREAST CANC UNIT,LONDON SE1 9RT,ENGLAND
[5] CHRISTIE HOSP,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND
[6] MRC,LONDON W1N 4AL,ENGLAND
关键词
D O I
10.1136/bmj.309.6952.457
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The United Kingdom Coordinating Committee on Cancer Research represents the major organisations funding cancer research in the United Kingdom. The deliberations of a working party convened by the committee to evaluate recently expressed concerns that the changes in the NHS threaten research, especially clinical trials to evaluate new treatments, are reported. A survey of contributors to trials coordinated by the committee showed that half are now experiencing difficulties in continuing to participate in clinical trials. The two major problems identified were lack of time and of staff, especially for NHS staff in non-teaching hospitals. Recent changes in junior doctors' hours and proposed reductions in the length of time for training will exacerbate this. It is possible to identify the direct and indirect excess costs of conducting research in the NHS, but currently the mechanism does not exist to designate funds specifically for this purpose. Consultation with the regional directors of research and development confirmed that the service increment for teaching and research is not the solution for this, Proposals are made to secure future clinical research in the NHS, including finance, indemnity, the licensing of new drugs, the greater use of nurse counsellors, and the value of cancer registries.
引用
收藏
页码:457 / 461
页数:5
相关论文
共 1 条
[1]  
1992, ASSESSING EFFECTS HL